Company / Operating Margin
Theravance Biopharma, Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-3.4%
FY2025
5-year range
-466.1% / -3.4%
FY2021-FY2025
Trend
+95.4%
vs FY2024
Sector context
#55 of 136
Health Care
What the data says
At -3.4%, Theravance Biopharma, Inc.'s operating margin ranks #55 of 136 in the Health Care sector. Operating Margin has increased for 4 consecutive years, from -466.1% in FY2021 to -3.4% in FY2025.
Based on SEC 10-K filings.
-3.4% in FY2025 with a 5-year CAGR of +410.8%.
Improved from -97.6% to -3.4% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +410.8pp
- 5-Year Change
- +410.8pp
- 10-Year Change
- -
Sector benchmark
#55 of 136 in Health CareTop 40% of 136This company -3.4% Sector average -778.9%
▼
+99.6% above sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s operating margin has grown for 4 consecutive years.
- In FY2025, operating margin increased 95.4% year-over-year.
- Currently 775.6pp above the Health Care sector average.
- Lowest operating margin in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -3.4% | +95.4% |
| FY2024 | -72.9% | +25.3% |
| FY2023 | -97.6% | +76.4% |
| FY2022 | -414.2% | +11.1% |
| FY2021 | -466.1% | -12.5% |
| FY2020 | -414.2% | +75.5% |
| FY2019 | -1690.7% | -355.7% |
| FY2018 | -371.0% | +95.6% |
| FY2017 | -8426.4% | -2171.5% |
| FY2016 | -371.0% | +99.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026